X
Upload your Marketing & Sales content on your company Virtual Booth, click HERE.
Details:
CNBX® RCC-33 is an novel cannabinoid-based formulation demonstrated with significant synergistic antitumor effect for the treatment of Colorectal Cancer.
Lead Product(s): CNBX RCC-33
Therapeutic Area: Oncology Product Name: CNBX RCC-33
Highest Development Status: PreclinicalProduct Type: Large molecule
Partner/Sponsor/Collaborator: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable October 18, 2022
Details:
CNBX RCC-33, a novel cannabinoid-based formulation, is used for the treatment of colorectal cancer currently being developed and prepared for a pre-IND meeting with the FDA and a first-in-human Phase I/II(a) validation study.
Lead Product(s): CNBX RCC-33
Therapeutic Area: Oncology Product Name: CNBX RCC-33
Highest Development Status: PreclinicalProduct Type: Small molecule
Partner/Sponsor/Collaborator: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable October 13, 2022
Details:
RCC-33, a novel cannabinoid-based formulation, demonstrated significant synergistic antitumor effect in pre clinical studies, for the treatment of colorectal cancer.
Lead Product(s): RCC-33
Therapeutic Area: Oncology Product Name: RCC-33
Highest Development Status: PreclinicalProduct Type: Small molecule
Partner/Sponsor/Collaborator: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable May 05, 2022
Details:
Under the agreement, Purisys will support an IND filing process, including providing all necessary and related information concerning Chemistry Manufacturing and Controls (CMC) in the form of a comprehensive technical package to be presented to the FDA regarding RCC-33.
Lead Product(s): RCC-33
Therapeutic Area: Oncology Product Name: RCC-33
Highest Development Status: PreclinicalProduct Type: Small molecule
Partner/Sponsor/Collaborator: Purisys LLC
Deal Size: Undisclosed Upfront Cash: Undisclosed
Deal Type: Agreement November 04, 2021
Details:
Cannabics™ RCC-33 is the first proprietary antitumor formulation we have released for in-vivo testing for treating cancer, including colorectal cancer and early intervention therapy for colorectal cancer patients.
Lead Product(s): RCC-33
Therapeutic Area: Oncology Product Name: RCC-33
Highest Development Status: PreclinicalProduct Type: Small molecule
Partner/Sponsor/Collaborator: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable October 18, 2021
Details:
The company is gearing up for submission of a pre-IND meeting package and meeting request to the US Food and Drug Administration regarding its Colorectal Cancer treatment drug candidate RCC-33.
Lead Product(s): RCC-33
Therapeutic Area: Oncology Product Name: RCC-33
Highest Development Status: PreclinicalProduct Type: Small molecule
Partner/Sponsor/Collaborator: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable June 03, 2021
Details:
The launching of the new research program for the development of Melanoma treatment follows a previous development by the company of Cannabics® RCC-33, who demonstrated a 33% reduction in tumor volume and a 35% increase in survival rate in recent in-vivo experiments in mice.
Lead Product(s): RCC-33
Therapeutic Area: Oncology Product Name: RCC-33
Highest Development Status: PreclinicalProduct Type: Small molecule
Partner/Sponsor/Collaborator: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable April 26, 2021
Details:
The announcement comes after the company was able to obtain a license from the Israeli Ministry of Health to conduct scientific research using Psylocibin and Psilocin in the company's in-house laboratory facilities in Rehovot, Israel.
Lead Product(s): Psilocybine
Therapeutic Area: Oncology Product Name: Undisclosed
Highest Development Status: UndisclosedProduct Type: Small molecule
Partner/Sponsor/Collaborator: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable April 20, 2021
Details:
The Dose Response Study comes in light of previously reported results indicating a 33% reduction in tumor volume and a 35% prolonged survival rate in mice inoculated with human colorectal cancer cells and exposed to Cannabics™ RCC-33.
Lead Product(s): RCC-33
Therapeutic Area: Oncology Product Name: RCC-33
Highest Development Status: PreclinicalProduct Type: Small molecule
Partner/Sponsor/Collaborator: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable March 31, 2021
Details:
The final study results demonstrate a significant and robust inhibitory effect on tumor growth, as evidenced by a 33% reduction in tumor volume in mice exposed to RCC-33 in comparison with sham control mice.
Lead Product(s): RCC-33
Therapeutic Area: Oncology Product Name: RCC-33
Highest Development Status: PreclinicalProduct Type: Small molecule
Partner/Sponsor/Collaborator: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable February 16, 2021
FULL SCREEN VIEW Click here to open all results in a new tab [this preview display 10 results] 
Market Place
